Normal view MARC view ISBD view

Efficacy of EZH2 inhibitory drugs in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas. [electronic resource]

By:

Lindsay, Cameron D

Contributor(s):

Producer: 20180521Description: 95 p. digitalISSN:

1868-7083

Subject(s):

Online resources:

Available from publisher's website

In: Clinical epigenetics vol. 9

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

to post a comment.

Back to results

1 Pharmacologic-Based Methods of Adherence Assessment in HIV Prevention.
by Brooks, Kristina M
2 Drug interactions in HIV treatment: complementary & alternative medicines and over-the-counter products.
by Brooks, Kristina M
3 Tenofovir alafenamide use in pregnant and lactating women living with HIV.
by Eke, Ahizechukwu C
4 Integrase Inhibitors: After 10 Years of Experience, Is the Best Yet to Come?
by Brooks, Kristina M
5 National Institutes of Health Perspective on Reports of Gadolinium Deposition in the Brain.
by Malayeri, Ashkan A
6 The role of jab1, a putative downstream effector of the neurotrophic cytokine macrophage migration inhibitory factor (MIF) in zebrafish inner ear hair cell development.
by Weber, Loren J
7 Alterations in Hydrocortisone Pharmacokinetics in a Patient With Congenital Adrenal Hyperplasia Following Bariatric Surgery.
by Mallappa, Ashwini
8 Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1/M2 translation.
by Beigel, John H
9 Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor.
by Ibrahim, Mustafa E
10 Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
by Aizire, Jim
11 Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration.
by Brooks, Kristina M
12 Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.
by Kumar, Parag
13 A Role for Low Density Lipoprotein Receptor-Related Protein 1 in the Cellular Uptake of Tissue Plasminogen Activator in the Lungs.
by Lin, Swan
14 Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers.
by Gordon, Lori A
15 Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?
by Brooks, Kristina M
16 Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir.
by Brooks, Kristina M
17 Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine.
by Brooks, Kristina M
18 Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate.
by Brooks, Kristina M
19 Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients.
by Kim, Hanna
20 Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer.
by Giovinazzo, Hugh